<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37474625</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Spatial proteomics landscape and immune signature analysis of renal sample of lupus nephritis based on laser-captured microsection.</ArticleTitle><Pagination><StartPage>1603</StartPage><EndPage>1620</EndPage><MedlinePgn>1603-1620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-023-01767-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to reveal a spatial proteomic and immune signature of kidney function regions in lupus nephritis (LN).</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The laser capture microdissection (LCM) was used to isolate the glomerulus, tubules, and interstitial of the kidney from paraffin samples. The data-independent acquisition (DIA) method was used to collect proteomics data. The bioinformatic analysis was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 49,658 peptides and 4056 proteins were quantitated. Our results first showed that a high proportion of activated NK cells, naive B cells, and neutrophils in the glomerulus, activated NK cells in interstitial, and resting NK cells were accumulated in tubules in LN. The immune-related function analysis of differential expression proteins in different regions indicated that the glomerulus and interstitial were major sites of immune disturbance and regulation connected with immune response activation. Furthermore, we identified 7, 8, and 9 hub genes in LN's glomerulus, renal interstitial, and tubules. These hub genes were significantly correlated with the infiltration of immune cell subsets. We screened out ALB, CTSB, LCN2, A2M, CDC42, VIM, LTF, and CD14, which show higher performance as candidate biomarkers after correlation analysis with clinical indexes. The function within three regions of the kidney was analyzed. The differential expression proteins (DEGs) between interstitial and glomerulus were significantly enriched in the immune-related biological processes, and myeloid leukocyte-mediated immunity and cellular response to hormone stimulus. The DEGs between tubules and glomerulus were significantly enriched in cell activation and leukocyte-mediated immunity. While the DEGs between tubules and interstitial were enriched in response to lipid, antigen processing, and presentation of peptide antigen response to oxygen-containing compound, the results indicated a different function within kidney regions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Collectively, we revealed spatial proteomics and immune signature of LN kidney regions by combined using LCM and DIA.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Fengping</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen Peking University, The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tang</LastName><ForeName>Donge</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Zhifeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Second Department of Urology, Affiliated Hospital of Guilin Medical University, Guangxi, 541001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yueqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yinxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hanyong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinzhou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dongzhou</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qingwen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, 5218036, Guangdong, China. wqw_sw@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Zuying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking University Shenzhen Hospital, Shenzhen Peking University, The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, Guangdong, China. xiongzy2005@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, 518020, Guangdong, China. daiyong22@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The First Affiliated Hospital, Anhui University of Science and Technology, Huainan, 232001, Anhui, China. daiyong22@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JCYJ20210324113013035</GrantID><Agency>Science, Technology and Innovation Commission of Shenzhen Municipality</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007678" MajorTopicYN="N">Kidney Glomerulus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007834" MajorTopicYN="N">Lasers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glomerulus</Keyword><Keyword MajorTopicYN="N">Immune</Keyword><Keyword MajorTopicYN="N">Interstitial</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Tubules</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>20</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37474625</ArticleId><ArticleId IdType="pmc">PMC10499763</ArticleId><ArticleId IdType="doi">10.1007/s00011-023-01767-3</ArticleId><ArticleId IdType="pii">10.1007/s00011-023-01767-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 2019;71:403&#x2013;410. doi: 10.1002/art.40729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40729</ArticleId><ArticleId IdType="pmc">PMC6393198</ArticleId><ArticleId IdType="pubmed">30225916</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76:265&#x2013;281. doi: 10.1053/j.ajkd.2019.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6:7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20:902&#x2013;914. doi: 10.1038/s41590-019-0398-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0398-x</ArticleId><ArticleId IdType="pmc">PMC6726437</ArticleId><ArticleId IdType="pubmed">31209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis. 2014;63:677&#x2013;690. doi: 10.1053/j.ajkd.2013.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2013.11.023</ArticleId><ArticleId IdType="pmc">PMC4159074</ArticleId><ArticleId IdType="pubmed">24411715</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Teh CL, Phui VE, Ling GR, Ngu LS, Wan SA, Tan CH. Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience. Clin Kidney J. 2018;11:56&#x2013;61. doi: 10.1093/ckj/sfx063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfx063</ArticleId><ArticleId IdType="pmc">PMC5798016</ArticleId><ArticleId IdType="pubmed">29423203</ArticleId></ArticleIdList></Reference><Reference><Citation>Leatherwood C, Speyer CB, Feldman CH, D'Silva K, G&#xf3;mez-Puerta JA, Hoover PJ, et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Semin Arthritis Rheum. 2019;49:396&#x2013;404. doi: 10.1016/j.semarthrit.2019.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.06.002</ArticleId><ArticleId IdType="pmc">PMC6888990</ArticleId><ArticleId IdType="pubmed">31277928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011;63:865&#x2013;874. doi: 10.1002/acr.20441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20441</ArticleId><ArticleId IdType="pmc">PMC3106120</ArticleId><ArticleId IdType="pubmed">21309006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko K, Wang J, Perper S, Jiang Y, Yanez D, Kaverina N, et al. Bcl-2 as a therapeutic target in human tubulointerstitial inflammation. Arthritis Rheumatol. 2016;68:2740&#x2013;2751. doi: 10.1002/art.39744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39744</ArticleId><ArticleId IdType="pmc">PMC5083145</ArticleId><ArticleId IdType="pubmed">27159593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao DA, Arazi A, Wofsy D, Diamond B. Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nat Rev Nephrol. 2020;16:238&#x2013;250. doi: 10.1038/s41581-019-0232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-019-0232-6</ArticleId><ArticleId IdType="pmc">PMC7251304</ArticleId><ArticleId IdType="pubmed">31853010</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Rao DA, Mohan C, Zhang T, Rosenberg A, Fenaroli P, et al. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol. 2022;74:829&#x2013;839. doi: 10.1002/art.42023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42023</ArticleId><ArticleId IdType="pmc">PMC9050800</ArticleId><ArticleId IdType="pubmed">34783463</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689&#x2013;695. doi: 10.1038/ki.1984.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248&#x2013;262. doi: 10.1016/j.celrep.2016.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.019</ArticleId><ArticleId IdType="pubmed">28052254</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453&#x2013;457. doi: 10.1038/nmeth.3337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther. 2011;13:243. doi: 10.1186/ar3433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3433</ArticleId><ArticleId IdType="pmc">PMC3308063</ArticleId><ArticleId IdType="pubmed">22078750</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73:121&#x2013;131. doi: 10.1002/art.41466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41466</ArticleId><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:100&#x2013;107. doi: 10.1136/annrheumdis-2021-220920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985;134:852&#x2013;857. doi: 10.4049/jimmunol.134.2.852.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.134.2.852</ArticleId><ArticleId IdType="pubmed">3871218</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzi L, Merville P, Demini&#xe8;re C, Moreau JF, Combe C, Pellegrin JL, et al. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum. 2007;56:2362&#x2013;2370. doi: 10.1002/art.22654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22654</ArticleId><ArticleId IdType="pubmed">17599764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Wang M, Zhang J, Feng X, Liu Z, Cheng Z. Association between tubulointerstitial CD8+T cells and renal prognosis in lupus nephritis. Int Immunopharmacol. 2021;99:107877. doi: 10.1016/j.intimp.2021.107877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107877</ArticleId><ArticleId IdType="pubmed">34217995</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolff S, Abdulahad WH, Arends S, van Dijk MC, Limburg PC, Kallenberg CG, et al. Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. Arthritis Res Ther. 2013;15:R36. doi: 10.1186/ar4189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4189</ArticleId><ArticleId IdType="pmc">PMC3672789</ArticleId><ArticleId IdType="pubmed">23445537</ArticleId></ArticleIdList></Reference><Reference><Citation>von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75:1407&#x2013;1415. doi: 10.1136/annrheumdis-2015-207776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207776</ArticleId><ArticleId IdType="pubmed">26324847</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatadri R, Sabapathy V, Dogan M, Sharma R. Targeting regulatory T cells for therapy of lupus nephritis. Front Pharmacol. 2021;12:806612. doi: 10.3389/fphar.2021.806612.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.806612</ArticleId><ArticleId IdType="pmc">PMC8775001</ArticleId><ArticleId IdType="pubmed">35069220</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849&#x2013;859. doi: 10.1038/nri2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2889</ArticleId><ArticleId IdType="pmc">PMC3046807</ArticleId><ArticleId IdType="pubmed">21107346</ArticleId></ArticleIdList></Reference><Reference><Citation>Parietti V, Monneaux F, D&#xe9;cossas M, Muller S. Function of CD4+, CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells. Arthritis Rheum. 2008;58:1751&#x2013;1761. doi: 10.1002/art.23464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23464</ArticleId><ArticleId IdType="pubmed">18512811</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong L, Wang Y, Zhou L, Bai X, Wu S, Zhu F, et al. Activation of toll-like receptor-7 exacerbates lupus nephritis by modulating regulatory T cells. Am J Nephrol. 2014;40:325&#x2013;344. doi: 10.1159/000368204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000368204</ArticleId><ArticleId IdType="pubmed">25341693</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177:1451&#x2013;1459. doi: 10.4049/jimmunol.177.3.1451.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.3.1451</ArticleId><ArticleId IdType="pubmed">16849451</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Guo Y, Qian Q, Fu M, Lei S, Zhang Y, et al. Mendelian randomization analysis revealed potential causal factors for systemic lupus erythematosus. Immunology. 2020;159:279&#x2013;288. doi: 10.1111/imm.13144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13144</ArticleId><ArticleId IdType="pmc">PMC7011638</ArticleId><ArticleId IdType="pubmed">31670388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Li W, Zhang Z, Tang X, Wu S, Yao G, et al. Lipocalin-2 exacerbates lupus nephritis by promoting Th1 cell differentiation. J Am Soc Nephrol. 2020;31:2263&#x2013;2277. doi: 10.1681/ASN.2019090937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2019090937</ArticleId><ArticleId IdType="pmc">PMC7609012</ArticleId><ArticleId IdType="pubmed">32646856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>